Research programme: protein-protein interaction inhibitors - Priaxon/Ludwig-Maximilians-University
Latest Information Update: 28 Jul 2018
Price :
$50 *
At a glance
- Originator Priaxon
- Developer Ludwig-Maximilians-University; Priaxon
- Class Small molecules
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in Germany
- 08 Jul 2013 Priaxon and Ludwig-Maximillians-University receive grant from Bavarian Research Foundation for development of inhibitors of protein-protein interactions in Cancer
- 08 Jul 2013 Early research in Cancer in Germany (unspecified route)